{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:06:36Z","timestamp":1778551596027,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.neuropharm.2007.10.010","type":"journal-article","created":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T22:04:10Z","timestamp":1195077850000},"page":"405-416","source":"Crossref","is-referenced-by-count":64,"title":["Effects of aripiprazole\/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats"],"prefix":"10.1016","volume":"54","author":[{"given":"R.E.","family":"Nordquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Risterucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"von Kienlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"K\u00fcnnecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Freichel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Spooren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2007.10.010_bib1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/00004647-199611000-00019","article-title":"Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow","volume":"16","author":"Alsop","year":"1996","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0278-5846(94)00114-W","article-title":"Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens","volume":"19","author":"Amano","year":"1995","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00210-006-0092-z","article-title":"In vivo occupancy of dopamine D(2) receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles","volume":"373","author":"Assi\u00e9","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib4","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/sj.npp.1301015","article-title":"Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade","volume":"31","author":"Auclair","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-007-0762-7","article-title":"Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats","volume":"193","author":"Auclair","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/bjp.186.1.7","article-title":"Partial agonism and schizophrenia","volume":"186","author":"Bolonna","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-007-0698-y","article-title":"In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain","volume":"191","author":"Bortolozzi","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","article-title":"Effects of novel antipsychotics with mixed D(2) antagonist\/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat","volume":"49","author":"Bruins Slot","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0924-977X(03)00007-5","article-title":"Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophrenia","volume":"13","author":"Daenen","year":"2003","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1522-2594(199907)42:1<206::AID-MRM28>3.0.CO;2-Q","article-title":"Fast T1 mapping on a whole-body scanner","volume":"42","author":"Deichmann","year":"1999","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-006-0658-y","article-title":"The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice","volume":"191","author":"Fejgin","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib15","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1517\/14656566.6.12.2091","article-title":"Aripiprazole","volume":"6","author":"Fleischhacker","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0091-3057(95)02096-9","article-title":"Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats","volume":"53","author":"Fujikawa","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"Cmaj"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib20","first-page":"258","article-title":"FLASH imaging. Rapid NMR imaging using low flip-angle pulses","volume":"67","author":"Haase","year":"1986","journal-title":"J.\u00a0Magn. Reson"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib21","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000904","article-title":"Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychol. Med. Monogr. Suppl."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib26","first-page":"329","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1440-1819.2003.01072.x","article-title":"Pathogenesis of schizophrenia: Part I. Symptomatology, cognitive characteristics and brain morphology","volume":"57","author":"Kurachi","year":"2003","journal-title":"Psychiatry Clin. Neurosci"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1300.063","article-title":"Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment","volume":"1003","author":"Laruelle","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0893-133X(00)00137-8","article-title":"To model a psychiatric disorder in animals: schizophrenia as a reality test","volume":"23","author":"Lipska","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib34","first-page":"853","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-004-1792-z","article-title":"Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia","volume":"174","author":"Moghaddam","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(96)00350-0","article-title":"Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area","volume":"310","author":"Momiyama","year":"1996","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib37","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0924-977X(06)70242-5","article-title":"Atypical and typical antipsychotics differentially reverse abnormal brain functional MRI signals in a neurodevelopmental model of schizophrenia","volume":"16","author":"Moreau","year":"2006","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib38","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib39","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0924-977X(06)70563-6","article-title":"Effects of aripiprazole\/OPC-14597 on pharmacological models of psychosis in rats","volume":"16","author":"Nordquist","year":"2006","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib40","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/nbm.956","article-title":"A study paradigm allowing compensation of multiple high-resolution rCBV-maps for the examination of drug effects","volume":"18","author":"Rausch","year":"2005","journal-title":"NMR Biomed"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00213-005-2204-8","article-title":"Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia","volume":"180","author":"Risterucci","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib44","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"issue":"Suppl. 9","key":"10.1016\/j.neuropharm.2007.10.010_bib46","first-page":"9","article-title":"The neurobiology of cognition in schizophrenia","volume":"67","author":"Tamminga","year":"2006","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib47","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1124\/jpet.106.113084","article-title":"Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition","volume":"320","author":"Van den Buuse","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1073\/pnas.89.1.212","article-title":"Magnetic resonance imaging of perfusion using spin inversion of arterial water","volume":"89","author":"Williams","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-7634(03)00035-6","article-title":"Schizophrenia: from phenomenology to neurobiology","volume":"27","author":"Wong","year":"2003","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2006.07.008","article-title":"Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties","volume":"546","author":"Wood","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2007.10.010_bib51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2007.10.010_bib52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2005.06.035","article-title":"Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex","volume":"387","author":"Zocchi","year":"2005","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390807003292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390807003292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:51:20Z","timestamp":1546476680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390807003292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0028390807003292"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2007.10.010","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}